Technical Analysis for CLVS - Clovis Oncology, Inc.

Grade Last Price % Change Price Change
grade F 20.88 0.38% 0.08
CLVS closed up 0.38 percent on Thursday, April 18, 2019, on 73 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CLVS trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Multiple of Ten Bullish Other 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 0.38%
Lower Bollinger Band Walk Weakness 0.38%
Below Lower BB Weakness 0.38%

Older signals for CLVS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Biopharmaceutical Disease Chemical Compounds Organic Compounds Drug Discovery Breast Cancer Non Small Cell Lung Cancer Lung Cancer Treatment Of Non Small Cell Lung Cancer Epidermal Growth Factor Receptor Lactams Indoles Gastrointestinal Stromal Tumor Heterocyclic Compounds
Is CLVS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 53.9
52 Week Low 11.5
Average Volume 1,612,122
200-Day Moving Average 27.7029
50-Day Moving Average 25.5002
20-Day Moving Average 23.695
10-Day Moving Average 23.058
Average True Range 1.3526
ADX 30.42
+DI 9.6959
-DI 34.3409
Chandelier Exit (Long, 3 ATRs ) 22.2722
Chandelier Exit (Short, 3 ATRs ) 23.8578
Upper Bollinger Band 26.8449
Lower Bollinger Band 20.5451
Percent B (%b) 0.05
BandWidth 26.587044
MACD Line -1.1985
MACD Signal Line -0.7869
MACD Histogram -0.4116
Fundamentals Value
Market Cap 1.02 Billion
Num Shares 48.8 Million
EPS -8.90
Price-to-Earnings (P/E) Ratio -2.35
Price-to-Sales 167.14
Price-to-Book 10.56
PEG Ratio 0.12
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.68
Resistance 3 (R3) 22.52 21.76 22.38
Resistance 2 (R2) 21.76 21.30 21.84 22.28
Resistance 1 (R1) 21.32 21.02 21.54 21.48 22.18
Pivot Point 20.56 20.56 20.67 20.64 20.56
Support 1 (S1) 20.12 20.10 20.34 20.28 19.58
Support 2 (S2) 19.36 19.82 19.44 19.48
Support 3 (S3) 18.92 19.36 19.38
Support 4 (S4) 19.08